Geneva Capital Management LLC Invests $6.69 Million in Veeva Systems Inc. $VEEV

Geneva Capital Management LLC purchased a new stake in shares of Veeva Systems Inc. (NYSE:VEEV) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 22,471 shares of the technology company’s stock, valued at approximately $6,694,000.

Other institutional investors also recently bought and sold shares of the company. GPS Wealth Strategies Group LLC lifted its position in Veeva Systems by 196.4% during the third quarter. GPS Wealth Strategies Group LLC now owns 83 shares of the technology company’s stock valued at $25,000 after buying an additional 55 shares during the period. Raiffeisen Bank International AG purchased a new stake in shares of Veeva Systems in the third quarter worth $28,000. OLD Second National Bank of Aurora purchased a new stake in Veeva Systems during the 3rd quarter valued at about $30,000. Cary Street Partners Investment Advisory LLC increased its stake in Veeva Systems by 58.3% during the 2nd quarter. Cary Street Partners Investment Advisory LLC now owns 133 shares of the technology company’s stock valued at $38,000 after purchasing an additional 49 shares in the last quarter. Finally, Elevation Point Wealth Partners LLC bought a new position in shares of Veeva Systems in the second quarter worth approximately $41,000. 88.20% of the stock is owned by institutional investors.

Trending Headlines about Veeva Systems

Here are the key news stories impacting Veeva Systems this week:

• Positive Sentiment: Veeva acquired AI chat specialist Ostro for roughly $100M to add an AI-driven, compliant brand‑engagement chat tool for patients and HCPs — expands Commercial Cloud capabilities and product moat. Veeva shells out $100M for Ostro and its AI chat tool for pharma brand engagement
• Positive Sentiment: AOP Health standardized on Veeva’s Industry Cloud across R&D, quality, commercial and data — a notable customer win that supports recurring SaaS revenue and cross‑cloud adoption. AOP Health Standardizes on Veeva Industry Cloud for Life Sciences Across All Business Areas
• Positive Sentiment: Q4 results beat expectations with stronger demand for modernization (safety, R&D) and expansion among top 20 pharma customers; management emphasized scalable, automated core systems as the main growth driver. These fundamentals support revenue durability and the long‑term SaaS upsell story. 5 Revealing Analyst Questions From Veeva Systems’s Q4 Earnings Call
• Neutral Sentiment: Analyst/investor attention articles (Zacks, market commentary) highlight interest in Veeva but don’t add new material facts — they may increase trading volume but are unlikely alone to change fundamentals. Veeva Systems Inc. (VEEV) is Attracting Investor Attention: Here is What You Should Know
• Negative Sentiment: Citigroup lowered its expectations/price target for Veeva, signaling analyst concern that recent moves (acquisition spend, guidance cadence) or valuation may not justify current multiples — analyst downgrades can pressure the stock near term. Citigroup Has Lowered Expectations for Veeva Systems (NYSE:VEEV) Stock Price

Insider Buying and Selling at Veeva Systems

In related news, insider Thomas D. Schwenger sold 1,000 shares of the business’s stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $231.43, for a total value of $231,430.00. Following the completion of the transaction, the insider owned 23,204 shares of the company’s stock, valued at approximately $5,370,101.72. The trade was a 4.13% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 10.30% of the stock is currently owned by company insiders.

Veeva Systems Stock Down 1.4%

Veeva Systems stock opened at $186.96 on Thursday. The company’s 50 day moving average is $201.48 and its two-hundred day moving average is $245.18. Veeva Systems Inc. has a 52-week low of $168.13 and a 52-week high of $310.50. The firm has a market cap of $30.73 billion, a PE ratio of 34.56, a price-to-earnings-growth ratio of 1.31 and a beta of 1.09.

Veeva Systems (NYSE:VEEV) last issued its quarterly earnings data on Wednesday, March 4th. The technology company reported $2.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.94 by $0.12. Veeva Systems had a return on equity of 14.11% and a net margin of 28.44%.The company had revenue of $835.95 million for the quarter, compared to analyst estimates of $810.95 million. During the same quarter last year, the company posted $1.74 earnings per share. The business’s quarterly revenue was up 16.0% compared to the same quarter last year. Veeva Systems has set its FY 2027 guidance at 8.850- EPS and its Q1 2027 guidance at 2.130-2.14 EPS. On average, equities research analysts anticipate that Veeva Systems Inc. will post 4.35 earnings per share for the current fiscal year.

Veeva Systems declared that its board has approved a stock repurchase program on Monday, January 5th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the technology company to purchase up to 5.5% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board believes its stock is undervalued.

Analysts Set New Price Targets

VEEV has been the subject of a number of recent research reports. BMO Capital Markets assumed coverage on Veeva Systems in a research note on Thursday, November 13th. They set a “market perform” rating and a $300.00 price target for the company. Wells Fargo & Company lowered their price objective on Veeva Systems from $333.00 to $317.00 and set an “overweight” rating on the stock in a research report on Thursday, March 5th. Piper Sandler decreased their price target on Veeva Systems from $355.00 to $285.00 and set an “overweight” rating on the stock in a report on Thursday, March 5th. Truist Financial reaffirmed a “buy” rating and set a $262.00 target price (down from $275.00) on shares of Veeva Systems in a research note on Thursday, March 5th. Finally, Wall Street Zen lowered shares of Veeva Systems from a “buy” rating to a “hold” rating in a report on Saturday, December 6th. Seventeen analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $283.70.

Veeva Systems Company Profile

Veeva Systems (NYSE: VEEV) is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.

Veeva’s product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management.